StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

4'-(1-Hydroxy-2-isopropylaminoethyl)methansulfonanilidhydrochlorid

Sotalol Hydrochloride

HCID 66245
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
959-24-0
Standard-SMILES
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl
InChIKey
VIDRYROWYFWGSY-UHFFFAOYSA-N
Summenformel
C12H21ClN2O3S
Durchschnittliche Molmasse
308,83 g/mol

Überblick

Sotalol hydrochloride is a hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. It has a role as a beta-adrenergic antagonist and an anti-arrhythmia drug. It contains a sotalol(1+).

Namen und Bezeichner

Bevorzugter Name
Sotalol Hydrochloride
IUPAC
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;hydrochloride
Lokaler Name
4'-(1-Hydroxy-2-isopropylaminoethyl)methansulfonanilidhydrochlorid
Englischer Name
Sotalol hydrochloride
Summenformel
C12H20N2O3S.ClH
Molmasse
308.83

Namen und Synonyme

Sotalol hydrochloride959-24-0Sotalol HCLBetapaceBetapace AFSotacorSotalexSorineSotylizeBerlexMJ 1999Darob
Weitere Namen anzeigen
MJ-1999DL-MJ 1999SOLATOL HCLmeadjohnson1999
Sotalol MonohydrochlorideHEC37C70XXIsopropylaminohydroxyethylmethanesulfonanilide hydrochloride4'-(1-Hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide monohydrochlorideNSC-337251NSC-760358DTXSID8021278N-Isopropyl-beta-(4-methanesulfonamidophenyl)ethanolamine hydrochloride

Datenbank-Bezeichner

CAS
959-24-0
PubChem CID
66245
ChEMBL
CHEMBL1700
ChEBI
CHEBI:9207
UNII
HEC37C70XX
EC Number
213-496-0

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
86,8 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
6
Schwere Atome
19
Formalladung
0
Komplexität
330

Experimentelle und physikochemische Eigenschaften

Solubility>46.3 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section166.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
218 · 218-220°C
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: 20 mg/mL
Aggregatzustand
powder
Farbe
white to off-white
Wasserlöslichkeit
Soluble in phosphate buffered saline, DMSO, ethanol, water, and methanol.
Major Application
pharmaceutical small molecule
InChI

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 1.4% (1 of 73) of reports.

Warning

H315 (94.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 73 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (94.5%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sotalol hydrochloride

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
hs_code
2935904000

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 6 Einträge

SOTALOL HYDROCHLORIDE

Cardiac Rhythm Alteration [PE]; Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]

SOTALOL HYDROCHLORIDE TABLES AF

Adrenergic beta-Antagonists [MoA]; Antiarrhythmic [EPC]; Cardiac Rhythm Alteration [PE]

SOTALOL HYDROCHLORIDE TABLETS AF

Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]; Cardiac Rhythm Alteration [PE]

MeSH Pharmacological Classification · 3 Einträge

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Anwendungen · 2 Einträge

BeschreibungSotalol is a non-selective antagonist of β-adrenergic receptors (β-ARs; IC50s = 8.9 and 5.2 μM for β1- and β2-ARs, respectively) and a class III antiarrhythmic agent. It decreases delayed outward potassium currents (IK) in guinea pig ventricular cells and prolongs action potential duration in electrically stimulated isolated guinea pig papillary muscles when used at a concentration of 100 μM. Sotalol decreases heart rate and increases blood pressure and the cardiac functional refractory period (FRP) in a canine model of ventricular tachycardia induced by programmed electrical stimulation (PES). Formulations containing sotalol have been used in the treatment of ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL).

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 479264
HRID 479264als Edukt
Reaktionsgleichung von HRID 651496
HRID 651496als Edukt
Reaktionsgleichung von HRID 1534563
HRID 1534563als Edukt
Reaktionsgleichung von HRID 2301241
HRID 2301241als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
InChI=1S/C12H20N2O3S.ClH/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17;/h4-7,9,12-15H,8H2,1-3H3;1H
InChIKey
VIDRYROWYFWGSY-UHFFFAOYSA-N
SMILES
C(C1C=CC(=CC=1)NS(=O)(=O)C)(O)CNC(C)C.Cl
CAS Datenbank
959 · 959-24-0(CAS DataBase Reference)
RTECS-Nr.
PB0826000
risk_code
36/37/38
Toxizität
LD50 in male mice, rats (mg/kg): 2600, 3450 orally; 670, 680 i.p.; LD50 orally in rabbits: 1000 mg/kg; LD50 i.p. in dogs: 330 mg/kg (Lish)
hazard_code
Xi
safety_code
26-36
Speicherklasse
11 - Combustible Solids

VerwendenSotalol hydrochloride is used as a potent beta adrenergic antagonist, prolongs the action potential and increases the refractory period. Sotalol hydrochloride is also considered a non-selective β blocker and a potassium channel blocker with an IC50 of 43 μM.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Hydrogenchlorid
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.